SASY.PA
Latest Trade
82.44EURChange
-0.79(-0.95%)Volume
662,562Today's Range
-
82.9652 Week Range
-
95.82As of on the Euronext Paris ∙ Minimum 15 minute delay
Previous Close | 83.23 |
|---|---|
Open | 82.80 |
Volume | 662,562 |
3M AVG Volume | 50.23 |
Today's High | 82.96 |
Today's Low | 82.13 |
52 Week High | 95.82 |
52 Week Low | 67.65 |
Shares Out (MIL) | 1,253.60 |
Market Cap (MIL) | 104,784.20 |
Forward P/E | 14.08 |
Dividend (Yield %) | 3.78 |
Sanofi To Name New European API Business Euroapi
Philip Morris Appoints Jorge Insuasty As Chief Life Sciences Officer
Sanofi To Acquire Kymab, Adding Ky1005 To Its Pipeline
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
Industry
Biotechnology & Drugs
Executive Leadership
Serge Weinberg
Independent Chairman of the Board
Paul Hudson
Chief Executive Officer, Member of the Executive Committee, Director
Jean-Baptiste Chasseloup de Chatillon
Chief Financial Officer, Executive Vice President, Member of the Executive Committee
Karen Linehan
Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee
Caroline Luscombe
Executive Vice President of Human Resources, Member of the Executive Committee
Price To Earnings (TTM) | 9.34 |
|---|---|
Price To Sales (TTM) | 2.78 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | 8.28 |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
The active pharmaceutical ingredients business being carved out by Sanofi will be called EUROAPI, the French drugmaker said on Tuesday, confirming it would decide whether to list the business by next year.
* Latest deal as Sanofi plays catch up in immunotherapy (Adds details, background)
* Britain asks doctors to start using them immediately (Adds statement from UK government, bullet points)
Treating critically ill COVID-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday.
* Phase I/II results show low immune response in older adults
GlaxoSmithKline said on Friday its goal to produce 1 billion doses of adjuvants - designed to boost COVID-19 vaccine efficacy - in 2021 remained in place but was under review following a development setback with partner Sanofi. .
Europe is better prepared than ever to ensure a COVID-19 vaccine reaches the population, Sanofi's chief executive said on Monday.
French drugmaker Sanofi continues to enroll patients for the treatment of diseases other than COVID-19 and maintains a 100% capacity to manufacture drugs, its chief executive said on Monday.
French drugmaker Sanofi has narrowed the gap against its rivals in the development of a COVID-19 vaccine, its Chief Executive said on Monday.
Activists called on pharmaceutical companies on Thursday to be transparent about the costs and terms of providing COVID-19 vaccines, saying they must be available and affordable for all.
Sanofi raised its 2020 earnings guidance for the second time this year after posting slightly stronger-than-expected third-quarter results on Thursday, helped by growth at its speciality care and vaccines units.
* COVAX alliance also has deals with AstraZeneca, Novavax (Adds details, background, Paris dateline)
French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their COVID-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization.
Clinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and U.S. biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals.
Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.
European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.
Sanofi is not involved in the COVID-19 human challenge trials reported to be launched in Britain and its potential vaccines are not being used in the trials, a spokesman for the French drugmaker said on Wednesday.
* Drugmakers also seek simpler compensation schemes for victims
* Many wealthy countries still to join (Adds price paid for deal in second paragraph)
Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.